Drugs / QMF149
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03100500 | Apr 2017 → Jul 2018 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-12-06 | Novartis Pharmaceuticals | Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy novartis.com ↗ |
| 2019-09-30 | Novartis Pharmaceuticals | Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma novartis.com ↗ |
| 2019-05-30 | Novartis Pharmaceuticals | Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QMF149 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03100500 ↗ |
| Route | Inhaled | “delivered as powder in hard capsules via Concept1 inhaler” NCT03100500 ↗ |